Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

brynpharma.com

Founded Year

2016

Stage

Series D | Alive

Total Raised

$83.25M

Last Raised

$28.28M | 1 yr ago

About Bryn Pharma

Bryn Pharma is advancing the Bryn Intranasal Epinephrine Spray (BRYN-NDS1C) product candidate, which is designed to provide patients with a life-saving treatment that fits in a pocket, is easy-to-use, and complies with practice parameters by containing two doses of epinephrine in one portable device, replacing the need to carry two emergency auto-injectors.

Bryn Pharma Headquarters Location

7101 Millstone Ridge Courty

Raleigh, North Carolina, 27614,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bryn Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bryn Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Bryn Pharma Patents

Bryn Pharma has filed 9 patents.

The 3 most popular patent topics include:

  • Beta blockers
  • Amines
  • Allergology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/29/2020

6/29/2021

Graphical projections, Ketones, Technical drawing, Antidotes, Allyl compounds

Grant

Application Date

1/29/2020

Grant Date

6/29/2021

Title

Related Topics

Graphical projections, Ketones, Technical drawing, Antidotes, Allyl compounds

Status

Grant

Latest Bryn Pharma News

Bryn Pharma Announces Completion of its Pivotal Study Comparing UTULY™ Epinephrine Intranasal Spray vs. 0.3 mg Epinephrine Autoinjector for the Treatment of Anaphylaxis

Sep 13, 2022

Bryn also announces completion of its human factor program and congestion study September 13, 2022 08:04 AM Eastern Daylight Time RALEIGH, N.C.--( BUSINESS WIRE )--Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today the completion of its pivotal study of UTULY™ (epinephrine nasal spray). The primary objective of the study was to evaluate whether the administration of UTULY could achieve a successful release profile with both short- and long-term pharmacokinetic (PK) and pharmacodynamic (PD) outcomes comparable to those seen with administration of the 0.3 mg epinephrine autoinjector (EpiPen, generic). Bryn intends to present study results at upcoming medical conferences. Epinephrine autoinjectors are the most widely prescribed treatment in the outpatient setting for anaphylaxis. While effective, autoinjectors have several limitations, including cost, fear of needles and convenience, leading people to avoid carrying the recommended two autoinjectors. This puts patients at greater risk of severe complications during an allergic reaction. “We are extremely encouraged with the results from our pivotal study comparing the needle-free UTULY nasal spray to the 0.3 mg IM autoinjector. Our findings have given us the confidence to move forward in the regulatory process. We are thrilled to be one step closer to improving the lives of people who live in fear of life-threatening allergic reactions and who are looking for alternatives to costly and cumbersome autoinjectors,” said David Dworaczyk, Ph.D., CEO of Bryn Pharma. “Completion of this study is a key milestone in the evolution of the treatment for anaphylaxis. Our hope is that the clinical trial results from Bryn’s innovative nasal product will support UTULY as an effective, safe and practical alternative to autoinjectors,” said Melinda Braskett, M.D., Associate Medical Director of the Gores Family Allergy Center at Children’s Hospital Los Angeles, and Bryn Pharma Scientific Advisor. About Anaphylaxis Anaphylaxis is a serious, life-threatening allergic reaction. The most common anaphylactic reactions are to foods, insect stings, medication and latex. 1 A major difference between anaphylaxis and other allergic reactions is that anaphylaxis typically involves more than one system of the body. 2 Estimates of Americans at risk for anaphylaxis range from 3.29 million to 40.9 million. 3 Early and fast administration of epinephrine (with quick uptake) using today’s most common method of delivery, the autoinjector (as opposed to a manual syringe which is used in a medical setting under the direct supervision of a doctor), is deemed critical to bringing the anaphylactic reaction under control. Because 30% of patients who develop anaphylaxis will require a second dose of epinephrine to control symptoms, practice parameters recommend that physicians provide patients with two autoinjectors. 4 If not treated properly, anaphylaxis can be fatal.1 However, studies have shown that the majority of people at risk for anaphylaxis often do not carry two epinephrine autoinjectors due in part to size and cost of the products, putting patients at greater risk of severe complications during an allergic reaction. 5 About Bryn Pharma Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com . Forward Looking Statements Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the Company’s products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the performance information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts

Bryn Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bryn Pharma Rank

  • When was Bryn Pharma founded?

    Bryn Pharma was founded in 2016.

  • Where is Bryn Pharma's headquarters?

    Bryn Pharma's headquarters is located at 7101 Millstone Ridge Courty, Raleigh.

  • What is Bryn Pharma's latest funding round?

    Bryn Pharma's latest funding round is Series D.

  • How much did Bryn Pharma raise?

    Bryn Pharma raised a total of $83.25M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.